Drugs / Exisulind
Exisulind
also known as
Aptosyn · APTOSYNTM · FGN-1 · Prevatec · Sulindac related compound b · sulindac sulfone · Sulindac sulphone
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT00072618 | Oct 2001 → Aug 2003 | non-small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1/2 | NCT00037609 | Jan 2001 → Feb 2003 | breast cancer, metastatic malignant neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary | ||||||
| Phase 2 | NCT00078910 | Aug 2003 → Sep 2006 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00166426 | Feb 2003 → May 2007 | prostate neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00052845 | Nov 2002 → Jan 2006 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00041314 | Oct 2002 → Jul 2005 | lung cancer | Eastern Cooperative Oncology Group | Completed | Met primary |
| Phase 2 | NCT00041054 | Jun 2002 → Aug 2004 | small cell lung carcinoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00166478 | Apr 2002 → Oct 2007 | prostate neoplasm | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00283803 | Mar 2002 → Oct 2011 | prostate cancer | University of Washington | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00026468 | Jul 1999 | colorectal cancer, small intestine cancer | University of Utah | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00085826 | Apr 2001 → Dec 2004 | non-small cell lung carcinoma | Astellas Pharma Inc | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | exisulind | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00026468 ↗ |
| Known as | Aptosyn | “Aptosyn (Exisulind)” NCT00085826 ↗ |
| Known as | APTOSYNTM | “Exisulind (sulindac sulfone, FGN-1, APTOSYNTM) is a sulfone metabolite of sulindac, a widely used nonsteroidal anti-inflammatory (NSAID) drug.” NCT00037609 ↗ |
| Known as | FGN-1 | “Exisulind (sulindac sulfone, FGN-1, APTOSYNTM) is a sulfone metabolite of sulindac, a widely used nonsteroidal anti-inflammatory (NSAID) drug.” NCT00037609 ↗ |
| Known as | Prevatec | ChEMBL registry synonym — accepted as the source's own label CHEMBL488025 ↗ |
| Known as | Sulindac related compound b | ChEMBL registry synonym — accepted as the source's own label CHEMBL488025 ↗ |
| Known as | sulindac sulfone | “Exisulind (sulindac sulfone, FGN-1, APTOSYNTM) is a sulfone metabolite of sulindac, a widely used nonsteroidal anti-inflammatory (NSAID) drug.” NCT00037609 ↗ |
| Known as | Sulindac sulphone | ChEMBL registry synonym — accepted as the source's own label CHEMBL488025 ↗ |
| Action | Inhibit | “Determine the ability of exisulind to inhibit growth and development of duodenal adenomas in patients with familial adenomatous polyposis.” NCT00026468 ↗ |
| Modality | Small molecule | — CHEMBL488025 ↗ |
| Route | Oral | “Patients receive oral exisulind 4 times daily.” NCT00026468 ↗ |